Education
About Us
Working with TipRanks
Follow Us
CalciMedica (CALC)
NASDAQ:CALC
CALC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.42 - $5.97
Previous CloseN/A
Volume2.29K
Average Volume (3M)69.97K
Market Cap
$44.29M
Enterprise Value$14.54M
Total Cash (Recent Filing)$17.96M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.47
Next Earnings
Nov 06, 2025EPS Estimate
-0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.40
Shares Outstanding13,972,177
10 Day Avg. Volume76,245
30 Day Avg. Volume69,971
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.33
Enterprise Value/Revenue242.26
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.63
Forecast
1Y Price Target
$16.00Price Target Upside404.73% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Clinical ProgressCalciMedica continued to make progress in advancing its lead clinical candidate, Auxora through the clinic.
Clinical ValidationClinical validation for Auxora in acute kidney injury can be found in the COVID-19 CARDEA study showing a 40% reduction in reported AKI in Auxora-treated patients as compared to placebo-treated patients.
FDA EngagementThe company recently held a productive initial meeting with the FDA to discuss the findings from the Phase 2b CAPRO trial and as well as a potential study design for their planned upcoming pivotal Phase 3 study.
Bears Say
Financial PerformanceCalciMedica announced 1Q25 financial results, posting EPS of ($0.36), compared to our estimate of ($0.33) and consensus of ($0.31).
Funding NeedsThe company is planning to hold an EOP2 with the FDA and expects to initiate a Phase 3 study in acute pancreatitis by YE25, pending additional funding.
Post-hoc AnalysisThe findings from the post-hoc analysis are especially relevant for the ongoing KOURAGE trial, as they were observed in patients with both kidney and respiratory failure.
CalciMedica News
CALC FAQ
What was CalciMedica’s price range in the past 12 months?
CalciMedica lowest stock price was $1.42 and its highest was $5.97 in the past 12 months.
What is CalciMedica’s market cap?
CalciMedica’s market cap is $44.29M.
When is CalciMedica’s upcoming earnings report date?
CalciMedica’s upcoming earnings report date is Nov 06, 2025 which is in 61 days.
How were CalciMedica’s earnings last quarter?
CalciMedica released its earnings results on Aug 12, 2025. The company reported -$0.4 earnings per share for the quarter, missing the consensus estimate of -$0.35 by -$0.05.
Is CalciMedica overvalued?
According to Wall Street analysts CalciMedica’s price is currently Undervalued.
Does CalciMedica pay dividends?
CalciMedica does not currently pay dividends.
What is CalciMedica’s EPS estimate?
CalciMedica’s EPS estimate is -0.41.
How many shares outstanding does CalciMedica have?
CalciMedica has 13,972,177 shares outstanding.
What happened to CalciMedica’s price movement after its last earnings report?
CalciMedica reported an EPS of -$0.4 in its last earnings report, missing expectations of -$0.35. Following the earnings report the stock price went down -10.145%.
Which hedge fund is a major shareholder of CalciMedica?
Currently, no hedge funds are holding shares in CALC
CalciMedica Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$16.00 (404.73% Upside)
$16.00 (404.73% Upside)
Blogger Sentiment
Bullish
CALC Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $205.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.1%
Last 30 Days ▲ 23.5%
Last 30 Days ▲ 23.5%
News Sentiment
Very Bearish
Bullish news 19%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-36.97%
12-Months-Change
Fundamentals
Return on Equity
-209.36%
Trailing 12-Months
Asset Growth
-9.37%
Trailing 12-Months
Company Description
CalciMedica
CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. The company is based in La Jolla, California.
CALC Stock 12 Month Forecast
Average Price Target
$16.00
▲(404.73% Upside)
Technical Analysis
Tenax Therapeutics
―
Ovid Therapeutics
―
Chemomab Therapeutics
―
ImmunoPrecise Antibodies
―
Longeveron
―
Ownership Overview
57.20% Insiders
3.02% Mutual Funds
21.15% Other Institutional Investors
16.38% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---